Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology
Related Posts
Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy[...]
LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus[...]
Lloyd MR, Weipert CM, Ali A, Solomon SR, Saha J, Lipsyc-Sharf MD, Hamilton EP, Kalinsky K, Brufsky AM, Bardia A, Zhang N, Wander SA. Clinical[...]